Trust Co. of Vermont Has $199,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Trust Co. of Vermont raised its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 36.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,019 shares of the medical research company’s stock after acquiring an additional 801 shares during the quarter. Trust Co. of Vermont’s holdings in Edwards Lifesciences were worth $199,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EW. Price T Rowe Associates Inc. MD raised its holdings in Edwards Lifesciences by 57.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after acquiring an additional 2,390,137 shares in the last quarter. CCLA Investment Management raised its stake in shares of Edwards Lifesciences by 100,739.7% during the 1st quarter. CCLA Investment Management now owns 1,406,714 shares of the medical research company’s stock worth $134,092,000 after purchasing an additional 1,405,319 shares in the last quarter. Swedbank AB acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $124,511,000. Sei Investments Co. boosted its holdings in shares of Edwards Lifesciences by 162.7% in the 1st quarter. Sei Investments Co. now owns 1,465,719 shares of the medical research company’s stock valued at $140,064,000 after buying an additional 907,688 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Edwards Lifesciences by 4.3% in the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after buying an additional 809,605 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,101,530.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,250 shares of company stock worth $1,099,238. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 2.6 %

EW stock opened at $70.27 on Friday. The company has a market cap of $42.34 billion, a PE ratio of 30.29, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The business has a 50-day simple moving average of $67.81 and a 200 day simple moving average of $79.18.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The company had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.66 EPS. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.71 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on EW. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. Wells Fargo & Company lowered their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Oppenheimer reiterated an “outperform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research note on Thursday, September 12th. UBS Group dropped their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 10th. Finally, JPMorgan Chase & Co. cut shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $105.00 to $72.00 in a research report on Thursday, July 25th. Fifteen equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $75.81.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.